The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis

Wang, A.; Wang, H.Y.; Liu, Y.; Zhao, Ming; Zhang, H.J.; Lu, Zhonghua; Fang, Yong-Yuan; Chen, X.F.; Liu, G.T.

doi:10.1016/j.ejso.2015.01.020

Cited by 231 publications

(166 citation statements)

References 36 publications

Supporting

Mentioning

148

Contrasting

Order By: Relevance

“…11 However, 3 recent meta-analyses found that PD-L1 overexpression was associated with a poor prognosis. [11][12][13] There is some indication that the method of establishing PD-L1 positivity influences the findings on disease outcome; in a subgroup analysis, Pan et al 13 noted that identification of PD-L1 positivity by IHC methods yielded an association with poorer outcome, whereas use of quantitative immunofluorescence yielded no prognostic value. The present study had a single-arm design and thus lacked the comparator arm that would permit assessment of the prognostic value of PD-L1 expression.…”

Section: Discussionmentioning

confidence: 99%

“…9,10 Furthermore, several recent meta-analyses have suggested a negative prognostic effect of tumor PD-L1 expression in this disease. [11][12][13] Pembrolizumab (MK-3475) is an anti-PD-1 monoclonal antibody of the immunoglobulin (Ig) G4-j isotype that blocks the binding of PD-1 with its ligands 14 ; pembrolizumab has demonstrated robust antitumor activity and has an acceptable toxicity profile in multiple tumor types, 2,[15][16][17] including NSCLC. 18,19 Pembrolizumab is currently approved in several countries for the treatment of advanced melanoma, and in the United States it is approved for the treatment of advanced NSCLC that expresses PD-L1 as determined by a test approved by the US Food and Drug Administration (FDA), with disease progression on or after platinumcontaining chemotherapy.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

Dolled‐Filhart

Roach²,

Toland³

et al. 2016

Archives of Pathology &Amp; Laboratory Medicine

105

View full text Add to dashboard Cite

Context.— Programmed death ligand-1 (PD-L1) expression by tumors may enable them to avoid immunosurveillance. Objective.— To develop a PD-L1 immunohistochemical assay using the 22C3 anti–PD-L1 murine monoclonal antibody on the Dako platform as a possible companion diagnostic for pembrolizumab in patients with non–small cell lung cancer. Design.— Tumor samples from 146 patients with non–small cell lung cancer treated with pembrolizumab in KEYNOTE-001 and for whom response data were available were scored according to their staining intensity by a single pathologist using 4 methods: percentage of tumor cells staining at any intensity (PS1), moderate/strong intensity (PS2), strong intensity (PS3), and H-score (PS1 + PS2 + PS3). The cutoff score for predicting response to pembrolizumab was determined using receiver operating characteristic analysis. Progression-free and overall survival were assessed in patients with measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (n = 146). Results.— The 4 scoring methods assessed performed similarly; PS1 with a 50% cutoff score is the simplest and easiest method to implement in practice. Response to pembrolizumab was observed in 19 of 44 patients (43%) with a PS1 score of 50% or higher and 8 of 102 patients (8%) with PS1 lower than 50% (odds ratio, 8.93). Median progression-free and overall survival was 4.0 months and not yet reached, respectively, for patients with a PS1 of 50% or higher, and 2.1 and 6.1 months, respectively, for those with PS1 lower than 50%. Conclusion.— The PD-L1 immunohistochemical assay shows the potential for enrichment of trial populations and as a companion diagnostic tool in non–small cell lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

Dolled‐Filhart

Roach²,

Toland³

et al. 2016

Archives of Pathology &Amp; Laboratory Medicine

105

View full text Add to dashboard Cite

show abstract

“…Studies have shown that surgically resected NSCLC expressing PD-L1 has a poorer postoperative survival, implying PD-L1 expressed by tumor cells is a likely immune avoidance mechanism. 6,7 Blockade of this PD-1-PD-L1 interaction by therapeutic monoclonal antibodies against either PD-1 (nivolumab, pembrolizumab) or PD-L1 (atezolizumab, durvalumab, avelumab) therefore seems a logical therapeutic approach based on a sound scientific rationale.…”

Section: Rationale For This Therapeutic Approachmentioning

confidence: 99%

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

Kerr¹,

Hirsch

2016

Archives of Pathology &Amp; Laboratory Medicine

124

View full text Add to dashboard Cite

The approval of anti-programmed death receptor (PD)-1 therapies for non–small cell lung cancer has directed the spotlight on programmed death ligand-1 (PD-L1) immunohistochemistry as the latest predictive biomarker potentially required in this disease. Several other drugs in this class will likely be approved in the future and each has been developed with a unique anti–PD-L1 immunohistochemistry test. The prospect of 5 drugs competing in the same treatment area, each possibly requiring PD-L1 immunohistochemistry testing, presents a challenge for pathologists unlike any previously faced. The key issue is whether laboratories will attempt to deliver the trial-validated assays for one or more of these treatments, or introduce instead one or more laboratory developed tests, or attempt to provide a single PD-L1 immunohistochemistry assay for all possible anti–PD-1 and anti–PD-L1 treatments that may be used. This paper discusses some of the issues, challenges, hazards, and possible solutions that have recently emerged in this most complex interface between cancer therapeutics and laboratory biomarker testing.

show abstract

“…Several retrospective and correlative studies examining the prognostic significance of tumor PD-L1 expression and PD-1 expression on tumor-infiltrating lymphocytes (TILs) have already been published, although the exact associations are somewhat controversial and appear to be dependent on tumor entity, treatment setting and the presence of other predictive factors or biomarkers. [19][20][21][22][23] Similar studies have not been reported in hematological malignancies, even though most of these tumor types, and especially lymphomas, are increasingly understood to closely interact with their surrounding microenvironment. 24 Importantly, we and others have shown that aberrant PD-L1 expression by lymphoma cells and increased expression of PD-1 on T cells are key mediators of impaired anti-tumor immune responses in a range of B-cell lymphomas, including DLBCL, FL and chronic lymphocytic leukemia (CLL), [25][26][27] and that inhibiting their interaction restores immune function in preclinical models.…”

Section: Catching Up With Solid Tumor Oncology: What Is the Evidence mentioning

confidence: 53%

Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

2016

View full text Add to dashboard Cite

show abstract

The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis

Cited by 231 publications

References 36 publications

Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Contact Info

Product

Resources

About